We could not find any results for:
Make sure your spelling is correct or try broadening your search.
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Top Brokers
Recent investor discussions on ADVFN about Oxford Biomedica Plc (OXB) reveal a mixed sentiment among shareholders, reflecting both optimism and caution regarding the company's performance and stock price trajectory. Participants expressed frustration over the company's share price behavior, with some highlighting a concerning trend of stocks rising initially only to decline later in the day. Notably, discussions centered around strategic developments like the potential integration of OXB within the CDMO market and its position in the wake of larger sector movements, including recent activities by Novo Holdings and Catalent that could potentially impact OXB's valuation.
Financially, forecasts suggest that OXB might see record sales next year, projected at around £180 million, which has led some investors to speculate about a favorable price target increase—some placing targets between £5 and £7.50. A key quote from an investor highlights the expectations surrounding OXB's performance: "Unless you are expecting some kind of as yet unforeseen disaster here, I'm not sure why you would think that a record revenue year... would only be worth another quid." Meanwhile, recent broker updates indicated a cautious approach, with JPMorgan raising OXB's price target to 490 pence but maintaining a 'neutral' stance, which reflects an underlying skepticism about the stock's immediate momentum despite optimistic revenue projections.
Show more
Oxford Biomedica Plc (OXB) announced an update on its total voting rights as of November 30, 2024. The company’s issued share capital comprises 105,938,933 ordinary shares, with no shares held in treasury. This figure is crucial for shareholders as it serves as the denominator for calculating their required notifications regarding interests in OXB, in accordance with FCA's Disclosure Guidance and Transparency Rules.
The release underscores the company's commitment to transparency and regulatory compliance within the financial landscape. As a cell and gene therapy contract development and manufacturing organization (CDMO), maintaining clear communication regarding voting rights is essential for shareholder engagement and investor confidence. Financial metrics or other developments specific to this period were not highlighted, indicating a focus on governance and corporate structure at this juncture.
Show more
Why the senior staff don't seem to be able to buy though Same logic the King has never denied the existence of UFO s so he must know there is some truth in it |
That's a great reminder of one of OXB's many current bow strings Taffy, but you maybe remember (from the 10 days of interims) that unless something unexpected happens with Monkeypox, the near-term upside is currently limited to manufacturing trial material for what will eventually be 2 large trials (universal covid + mpox which uses the same base and can be a combined vaccine). |
GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update |
"My honest opinion is that they are all embargoed for a reason unknown to us" |
Regarding no director buys - I think that the policy is that they should build a personal holding that is equivalent to an annual LTIP award. No idea what time frame that's over. |
By the way - I tried to send Harry an apology using a 'message' directly to him. But as he has me filtered/blocked, the message would not send. So he wouldn't have seen my post unless somebody forwarded it to him. Or he might have briefly unfiltered me to have a sneaky view, as he has admitted doing on the odd occasion. My apologies to all offended by my 'skirt'. |
You might have hit the nail on the head.If you haven't got a microscope and 'Doctor' before your name,you're really not worth bothering with! |
My thoughts too icejelly. A better thought than 'perhaps there is nothing yet worth betting on'. |
Could it be that the directors feel they have enough shares through their options? |
Gareth, |
I've just heard a rumour Dom that Welby will be the new host of MOTD and Lineker is going to become the new Archbishop of Canterbury. If true then our non-exec board dodged a couple of bullets there imho. |
HST, I have questioned, as you know what do our corporate brokers do for us publicly. Broker notes, price targets, bringing in new partners. I'm only a novice, perhaps there is more paddling beneath the water but I can't see it. Director buys, it's been months since we speculated why no director buys, there cannot be sensitive information which prevents director buys months before and significant signed off deal (can there?). |
Because nobody has told Frank that OXB has shareholders? |
Repeated more times than UKGold I know, but I think the random walk with the daily chart doesn't ever really mean anything on low volume. Something of a trend happening over a few days on better than normal daily volume then fair enough, but at the moment OXB is very quiet. |
Really funny to watch the britishbulls bot dealing system get in such a complete pickle this week over trading this share. Issued a sell order as price drifted back to 410, then needed to reverse it a day later when short sided so asked clients to move to cash and will no doubt move back to buy as share price drifts higher. LTBH can be somewhat less stressful (sometimes!).... |
Its going to be full steam ahead for US equities and all things crypto for a few days at least.As for the UK,Reeves budget and the threat of tariffs suggest a relatively drab performance by UK equities.Of course its worth noting that if, perchance,you were interested in getting involved in crypto,the FCA have decided,along with the European Union,that its downright unhealthy for your average punter to have anything to do with crypto.So US crypto ETFs are off limits,for example,to your average uk investor as a convenient means of sharing in this prospective Trump/Musk inspired bonanza.You can buy crypto through an exchange like Coinbase but its not a simple affair and involves an element of security risk.Why half the globe is permitted to run wild sampling a universe of investment opportunities while the other half suffer a 1984 Big Brother syndrome is not quite clear.There are self assigned parties out there who appear to believe that they know best and we need protecting from ourselves.Sorry to ramble off topic,its an age thing. |
The Trump victory seems to be influencing the investors into favouring certain parts of the market atm (e.g. BTC, US small cap) and I wonder what influence this has on the UK mid cap world especially with the recent budget influences to work through. |
Harry.....I've been quiet of late but I'm still here. Despite the threat of increased tariffs for goods manufactured in the U.K. or Europe, I still regard this share as being Trump neutral and thus far things appear to be developing nicely. Achieving sustainable profitability ASAP must be the key objective going forward: after that the general story should come more into play and plenty of influential people have eyes on here. Keep smiling Harry. |
I'm sure it's their own vector Phil and it seems to have done very little for Syncona this morning too. |
SJ, |
Do we think that is one of our clients Cousin? |
Autolus have received their FDA approval for commercial launch |
Dearie,dearie,me. |
Type | Ordinary Share |
Share ISIN | GB00BDFBVT43 |
Sector | Medicinal Chems,botanicl Pds |
Bid Price | 430.50 |
Offer Price | 431.50 |
Open | 430.00 |
Shares Traded | 23,068 |
Last Trade | 10:19:42 |
Low - High | 430.00 - 432.50 |
Turnover | 89.54M |
Profit | -184.16M |
EPS - Basic | -1.7479 |
PE Ratio | -2.47 |
Market Cap | 453.05M |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions